Survey of Risk-Based Quality Management Status and Establishment of Operational Model in Clinical Trials
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: With the release of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use E6 addendum, it is very important to establish risk-based quality management systems which meet good clinical practice. The aim of this research was to propose for risk-based quality management practices in the organizations that conduct clinical trials in South Korea. Materials and Methods: The survey participant pool consisted of domestic or multinational pharmaceutical companies and fullservice clinical research organizations operating in South Korea that had one or more clinical trials approved by the Korean Ministry of Food and Drug Safety in 2018. Results: Of the 97 selected companies, a total of 61 companies completed the survey. A total of 42 companies (68.9%) had employees designated to quality management activities. The minimum and maximum numbers of dedicated personnel for quality management were one and 12, respectively, and the average was three. Regarding the role of quality management personnel in companies, standard operating procedure management, issue/corrective action and preventive action (CAPA) management, and preparing inspection were selected the most (81%). The system considered to be the most important for risk management was monitoring system (41 companies, 67.2%), followed by both vendor management and CAPA management systems (17 companies, 27.9%). Conclusion: In the future, organizations conducting clinical and subsequent pilot studies trials in South Korea should follow these quality management practice to share information with each other.
Abstract
Purpose: With the release of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use E6 addendum, it is very important to establish risk-based quality management systems which meet good clinical practice. The aim of this research was to propose for risk-based quality management practices in the organizations that conduct clinical trials in South Korea. Materials and Methods: The survey participant pool consisted of domestic or multinational pharmaceutical companies and fullservice clinical research organizations operating in South Korea that had one or more clinical trials approved by the Korean Ministry of Food and Drug Safety in 2018. Results: Of the 97 selected companies, a total of 61 companies completed the survey. A total of 42 companies (68.9%) had employees designated to quality management activities. The minimum and maximum numbers of dedicated personnel for quality management were one and 12, respectively, and the average was three. Regarding the role of quality management personnel in companies, standard operating procedure management, issue/corrective action and preventive action (CAPA) management, and preparing inspection were selected the most (81%). The system considered to be the most important for risk management was monitoring system (41 companies, 67.2%), followed by both vendor management and CAPA management systems (17 companies, 27.9%). Conclusion: In the future, organizations conducting clinical and subsequent pilot studies trials in South Korea should follow these quality management practice to share information with each other.
참고문헌 (18)
- "Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). Current step 4 version"[URL]
- "Guidance for industry oversight of clinical investigations—a risk-based approach to monitoring"[URL]
- "Reflection paper on risk based quality management in clinical trials"[URL]
- Usher RW, "PhRMA BioResearch Monitoring Committee perspective on acceptable approaches for clinical trial monitoring", Drug Inf J, 44, pp.477~483 (2010)
- Brosteanu O, "Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials", Clin Trials, 6, pp.585~596 (2009)
- Tantsyura V, "Risk-based source data verification approaches : pros and cons", Drug Inf J, 44, pp.745~756 (2010)
- Baigent C, "Ensuring trial validity by data quality assurance and diversification of monitoring methods", Clin Trials, 5, pp.49~55 (2008)
- Buyse M, "The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials", Stat Med, 18, pp.3435~3451 (1999)
- "Building quality into clinical trials—an FDA perspective"[URL]
- "Workshop on quality risk management: making clinical trials fit for purpose"[URL]
- "Information of clinical trials in South Korea"[URL]
- "TransCelerate BioPharma Inc"[URL]
- Hennig M, "Current practice and perspectives in CRO oversight based on a survey performed among members of the German Association of Research-Based Pharmaceutical Companies(vfa)", Ger Med Sci, 15, pp.Doc02~ (2017)
- Rodríguez-Pérez J., "Handbook of investigation and effective CAPA systems" (2016), ASQ Quality Press
- Applied Clinical Trials Editors, "Clinical quality assurance benchmarking. Results of pharmaceutical R&D companies’ clinical quality assurance organization, strategies, resources, and activities are presented", Appl Clin Trials (2004)
- Hecht A, "Critical appraisal of clinical quality assurance based on benchmarking results: past-present–future", Appl Clin Trials (2015)
- Morrison BW, "A CTTI survey of current monitoring practices. Poster presentation", Society for Clinical Trials, 31st Annual Meeting (2010)
- Abraham A., "New survey measures the pulse of RBM & ICH-E6(R2) adoption in the clinical trials industry", Appl Clin Trials (2019)